← Back to Search

Tissue Matrix

Soft Tissue Augmentation for Implant Complications

N/A
Recruiting
Led By Lorenzo Tavelli, DDS, MS
Research Sponsored by Harvard Medical School (HMS and HSDM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3, 6, and 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial compares 2 ways to increase soft tissue around dental implants: using body tissue vs. artificial material with a special protein.

Who is the study for?
This trial is for adults over 18 with a single functional dental implant in the front of their mouth that needs more gum tissue. They must have good oral hygiene and overall health, with no untreated gum disease around the implant. Smokers or those with certain systemic conditions like diabetes or cancer are excluded.
What is being tested?
The study compares two methods for adding gum tissue to dental implants where there's not enough: using the patient's own tissue (CTG) versus a combination of donor skin matrix (ADM) and enamel matrix derivative.
What are the potential side effects?
Possible side effects may include discomfort, swelling, bleeding at the graft site, infection risk, and potential rejection or failure of the graft material.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3, 6, and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3, 6, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Soft tissue dehiscence depth
Secondary study objectives
3D Volumetric changes
Complete peri-implant soft tissue dehiscence (PSTD) coverage
Mucosal thickness changes
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Dermal matrix + EMDExperimental Treatment1 Intervention
Acellular dermal matrix and enamel matrix derivative
Group II: Connective tissue graftActive Control1 Intervention
Autogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized

Find a Location

Who is running the clinical trial?

Harvard Medical School (HMS and HSDM)Lead Sponsor
204 Previous Clinical Trials
1,316,657 Total Patients Enrolled
1 Trials studying Implant Complication
28 Patients Enrolled for Implant Complication
Lorenzo Tavelli, DDS, MSPrincipal InvestigatorHarvard School of Dental Medicine, Boston, USA
2 Previous Clinical Trials
58 Total Patients Enrolled
1 Trials studying Implant Complication
28 Patients Enrolled for Implant Complication

Media Library

Acellular Dermal Matrix + Enamel Matrix Derivative (Tissue Matrix) Clinical Trial Eligibility Overview. Trial Name: NCT05729607 — N/A
Implant Complication Research Study Groups: Dermal matrix + EMD, Connective tissue graft
Implant Complication Clinical Trial 2023: Acellular Dermal Matrix + Enamel Matrix Derivative Highlights & Side Effects. Trial Name: NCT05729607 — N/A
Acellular Dermal Matrix + Enamel Matrix Derivative (Tissue Matrix) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05729607 — N/A
~11 spots leftby Feb 2026